Medivation continues its pipeline expansion efforts beyond Xtandi by paying $410m up front for a Phase III PARP inhibitor from BioMarin. Novo Nordisk acquires a pair of diabetes-focused start-ups, while Immatics will establish a US subsidiary on the MD Anderson Cancer Center campus in Houston.

Deal is structured with significant upfront cash at $410m, but relatively low earn-out potential for a Phase III cancer candidate. It also gives Medivation two late-stage oncology compounds beyond Xtandi; CEO David Hung outlines strategy.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.